Mass General Hospital

Harvard Medical School

Archive | New Research

New research from the CWMH.

New Study at the CWMH: Course of ADHD During Pregnancy and the Postpartum

  About 1.4 million people in the U.S. have been diagnosed with ADHD, and about 60-80% of children diagnosed with ADHD will need to take their medication into adulthood. When girls diagnosed in childhood become reproductive-aged women, they face challenging decisions regarding how to proceed with their treatment when they are also family planning. There […]

Continue Reading · 0

Announcing the MGH Perinatal Depression Scale at the App Store

    We are very pleased to announce the release of the MGH Perinatal Depression Scale available free of charge on the App Store (https://appsto.re/us/-3X4jb.i). The MGHPDS smartphone app includes digital versions of perinatal depression screening tools including the Edinburgh Postpartum Depression Scale (EPDS) as well as other instruments which measure relevant symptoms associated with […]

Continue Reading · 0

New Study at the CWMH: Brexanolone (SAGE-547) for Postpartum Depression

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression.  SAGE-547, now called brexanolone, is a new type of antidepressant: a formulation of allopregnanolone, which is an endogenous, naturally occurring neuroactive steroid and a metabolite of progesterone.  Data from the most recent study of brexanolone was […]

Continue Reading · 0

New Research from the CWMH: Lithium During Pregnancy and Risk of Cardiovascular Malformations

  While we use lithium less commonly now than we have in the past, lithium is still one of the very best mood stabilizers we have.  And with regard to its reproductive safety, we have studies going back nearly 50 years.   In the 1970s, reports from the International Register of Lithium Babies suggested a […]

Continue Reading · 0

Press Release: Potential Treatment Option for Women Deciding to Discontinue Antidepressants During Pregnancy

Massachusetts General Hospital Efficacy Study Centers on EnBrace HR™ SUNSET, LA (PRWEB) OCTOBER 18, 2016: JayMac Pharmaceuticals is sponsoring a study at Massachusetts General Hospital to assess the efficacy of a pre-and post-natal supplement, EnBrace HR™, as a treatment for the prevention of depression in women with a history of Major Depressive Disorder who decide […]

Continue Reading · 0
Baby Belly from Wikimedia Commons

New Research from the CWMH: Prenatal Exposure to Atypical Antipsychotics Does Not Increase Risk of Malformations

The use of the newer “atypical” or second-generation antipsychotic agents continues to increase.  These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders.  Although most of the women taking atypical antipsychotics are of childbearing age, our information on the reproductive safety of these newer […]

Continue Reading · 0
Credit: Pregnant Woman from Wikimedia Commons

New Research from the CWMH: Newer Antipsychotics and Pregnancy

Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data on the reproductive safety of these newer atypical agents.  In response to this deficit, the National Pregnancy Registry for Atypical […]

Continue Reading · 0
Baby Belly from Wikimedia Commons

New Research from the CWMH: Reassuring Data from the National Pregnancy Registry of Atypical Antipsychotics

Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data on the reproductive safety of these newer atypical agents.  In response to this deficit, the National Pregnancy Registry for Atypical […]

Continue Reading · 0

New Research from the CWMH: Omega-3 Fatty Acids for Atypical Antipsychotic-Associated Hypertriglyceridemia

Dyslipidemia is a common side effect of atypical antipsychotics and, for a significant number of patients, may limit the acceptabillily of this class of drugs as an option for long-term treatment. This open trial tested the efficacy of omega-3 fatty acids for treating dyslipidemia associated with the use of atypical antipsychotics. Participants had hypertriglyceridemia (> […]

Continue Reading · 0

New Research from the CWMH: Armodafinil for Menopause-Related Fatigue

Several recent articles indicate that the burden of menopausal symptoms is greater than generally perceived.  About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the menopause phase.  For most, the symptoms are manageable, but for a sizeable subset of midlife women, these symptoms can negatively […]

Continue Reading · 0